Grifols, S.A is a drug manufacturers-general business based in the US. Grifols S-A shares (GRFS) are listed on the NASDAQ and all prices are listed in US Dollars. Grifols S-A employs 24,000 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Grifols S-A
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GRFS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- GRFS shares summary
- Compare share dealing platforms
- Is GRFS stock a buy or sell?
- Stock performance over time
- Can I short GRFS shares?
- Are GRFS shares over-valued?
- Grifols S-A's financials
- How volatile are GRFS shares?
- Does Grifols S-A pay a dividend?
- Have GRFS shares ever split?
- Other common questions
Grifols S-A stock price (NASDAQ: GRFS)Use our graph to track the performance of GRFS stocks over time.
Grifols S-A shares at a glance
|Latest market close||$17.49|
|52-week range||$14.42 - $19.95|
|50-day moving average||$16.76|
|200-day moving average||$17.30|
|Wall St. target price||$28.62|
|Dividend yield||$0.36 (2.31%)|
|Earnings per share (TTM)||$0.49|
Buy Grifols S-A shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Grifols S-A stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Grifols S-A price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||1.10%|
|3 months (2021-04-30)||-0.91%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Is Grifols S-A under- or over-valued?
Valuing Grifols S-A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Grifols S-A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Grifols S-A's P/E ratio
Grifols S-A's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Grifols S-A shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Grifols S-A's PEG ratio
Grifols S-A's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7786. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Grifols S-A's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Grifols S-A's EBITDA
Grifols S-A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a Grifols S-A's overall financial performance and is widely used to measure a its profitability.
Grifols S-A financials
|Revenue TTM||$5.2 billion|
|Operating margin TTM||17.34%|
|Gross profit TTM||$2.3 billion|
|Return on assets TTM||3.54%|
|Return on equity TTM||9.12%|
|Market capitalisation||$14.4 billion|
TTM: trailing 12 months
Shorting Grifols S-A shares
There are currently 4.0 million Grifols S-A shares held short by investors – that's known as Grifols S-A's "short interest". This figure is 0% down from 4.0 million last month.
There are a few different ways that this level of interest in shorting Grifols S-A shares can be evaluated.
Grifols S-A's "short interest ratio" (SIR)
Grifols S-A's "short interest ratio" (SIR) is the quantity of Grifols S-A shares currently shorted divided by the average quantity of Grifols S-A shares traded daily (recently around 539287.01472557). Grifols S-A's SIR currently stands at 7.47. In other words for every 100,000 Grifols S-A shares traded daily on the market, roughly 7470 shares are currently held short.
However Grifols S-A's short interest can also be evaluated against the total number of Grifols S-A shares, or, against the total number of tradable Grifols S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Grifols S-A's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Grifols S-A shares in existence, roughly 10 shares are currently held short) or 0.0036% of the tradable shares (for every 100,000 tradable Grifols S-A shares, roughly 4 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Grifols S-A.
Find out more about how you can short Grifols S-A stock.
Grifols S-A share dividends
Dividend payout ratio: 69.82% of net profits
Recently Grifols S-A has paid out, on average, around 69.82% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.86% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Grifols S-A shareholders could enjoy a 5.86% return on their shares, in the form of dividend payments. In Grifols S-A's case, that would currently equate to about $0.36 per share.
Grifols S-A's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Grifols S-A's most recent dividend payout was on 13 June 2021. The latest dividend was paid out to all shareholders who bought their shares by 2 June 2021 (the "ex-dividend date").
Have Grifols S-A's shares ever split?
Grifols S-A's shares were split on a 2:1 basis on 3 January 2016. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Grifols S-A shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Grifols S-A shares which in turn could have impacted Grifols S-A's share price.
Grifols S-A share price volatility
Over the last 12 months, Grifols S-A's shares have ranged in value from as little as $14.4225 up to $19.9538. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Grifols S-A's is 0.0952. This would suggest that Grifols S-A's shares are less volatile than average (for this exchange).
Grifols S-A overview
Grifols, S. A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy.
Grifols S-A in the news
Grifols: Q2 Earnings Snapshot
Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer
Frequently asked questionsWhat percentage of Grifols S-A is owned by institutions?
Currently 43.023% of Grifols S-A shares are held by institutions. How many people work for Grifols S-A?
Latest data suggests 24,000 work at Grifols S-A. When does the fiscal year end for Grifols S-A?
Grifols S-A's fiscal year ends in December. Where is Grifols S-A based?
Grifols S-A's address is: Avinguda de la Generalitat, 152, Barcelona, Spain, 08174 What is Grifols S-A's ISIN number?
Grifols S-A's international securities identification number is: US3984384087 What is Grifols S-A's CUSIP number?
Grifols S-A's Committee on Uniform Securities Identification Procedures number is: 398438200
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert